
EquitySector - HealthcareVery High Risk
NAV (22-Jan-26)
Returns (Since Inception)
Fund Size
₹40 Cr
Expense Ratio
0.23%
ISIN
INF247L01BB1
Minimum SIP
-
Exit Load
-
Inception Date
29 Jul 2022
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-1.49%
— (Cat Avg.)
3 Years
+22.73%
+20.98% (Cat Avg.)
Since Inception
+19.25%
— (Cat Avg.)
| Equity | ₹39.46 Cr | 99.88% |
| Others | ₹0.05 Cr | 0.12% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹5.29 Cr | 13.40% |
| Cipla Ltd | Equity | ₹2.49 Cr | 6.30% |
| Divi's Laboratories Ltd | Equity | ₹2.38 Cr | 6.01% |
| Dr Reddy's Laboratories Ltd | Equity | ₹2.26 Cr | 5.71% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹2.25 Cr | 5.70% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹2.1 Cr | 5.31% |
| Lupin Ltd | Equity | ₹1.49 Cr | 3.77% |
| Fortis Healthcare Ltd | Equity | ₹1.34 Cr | 3.40% |
| Laurus Labs Ltd | Equity | ₹1.26 Cr | 3.18% |
| Torrent Pharmaceuticals Ltd | Equity | ₹1.17 Cr | 2.97% |
| Aurobindo Pharma Ltd | Equity | ₹0.96 Cr | 2.43% |
| Alkem Laboratories Ltd | Equity | ₹0.94 Cr | 2.38% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.89 Cr | 2.25% |
| Mankind Pharma Ltd | Equity | ₹0.71 Cr | 1.81% |
| Biocon Ltd | Equity | ₹0.69 Cr | 1.75% |
| Zydus Lifesciences Ltd | Equity | ₹0.67 Cr | 1.70% |
| Ipca Laboratories Ltd | Equity | ₹0.58 Cr | 1.47% |
| Abbott India Ltd | Equity | ₹0.45 Cr | 1.14% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.44 Cr | 1.11% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.43 Cr | 1.09% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.42 Cr | 1.06% |
| Gland Pharma Ltd | Equity | ₹0.4 Cr | 1.00% |
| Neuland Laboratories Ltd | Equity | ₹0.38 Cr | 0.97% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.37 Cr | 0.94% |
| Sai Life Sciences Ltd | Equity | ₹0.36 Cr | 0.91% |
| Syngene International Ltd | Equity | ₹0.36 Cr | 0.91% |
| Wockhardt Ltd | Equity | ₹0.35 Cr | 0.88% |
| Ajanta Pharma Ltd | Equity | ₹0.34 Cr | 0.87% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.33 Cr | 0.84% |
| Piramal Pharma Ltd | Equity | ₹0.31 Cr | 0.78% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.29 Cr | 0.74% |
| Global Health Ltd | Equity | ₹0.29 Cr | 0.73% |
| OneSource Specialty Pharma Ltd | Equity | ₹0.28 Cr | 0.72% |
| Acutaas Chemicals Ltd | Equity | ₹0.26 Cr | 0.65% |
| Granules India Ltd | Equity | ₹0.25 Cr | 0.64% |
| Jubilant Pharmova Ltd | Equity | ₹0.25 Cr | 0.63% |
| Cohance Lifesciences Ltd | Equity | ₹0.25 Cr | 0.63% |
| Natco Pharma Ltd | Equity | ₹0.24 Cr | 0.60% |
| Pfizer Ltd | Equity | ₹0.22 Cr | 0.55% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹0.21 Cr | 0.52% |
| Poly Medicure Ltd | Equity | ₹0.2 Cr | 0.50% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.19 Cr | 0.48% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.18 Cr | 0.45% |
| Strides Pharma Science Ltd | Equity | ₹0.17 Cr | 0.44% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.16 Cr | 0.42% |
| Indegene Ltd | Equity | ₹0.16 Cr | 0.40% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.15 Cr | 0.38% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.15 Cr | 0.38% |
| Metropolis Healthcare Ltd | Equity | ₹0.15 Cr | 0.37% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.14 Cr | 0.34% |
| Procter & Gamble Health Ltd | Equity | ₹0.13 Cr | 0.34% |
| Concord Biotech Ltd | Equity | ₹0.13 Cr | 0.33% |
| Emcure Pharmaceuticals Ltd | Equity | ₹0.12 Cr | 0.31% |
| Aarti Pharmalabs Ltd | Equity | ₹0.11 Cr | 0.29% |
| Marksans Pharma Ltd | Equity | ₹0.11 Cr | 0.28% |
| Sanofi India Ltd | Equity | ₹0.11 Cr | 0.27% |
| Caplin Point Laboratories Ltd | Equity | ₹0.11 Cr | 0.27% |
| Shilpa Medicare Ltd | Equity | ₹0.1 Cr | 0.25% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.1 Cr | 0.25% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹0.09 Cr | 0.22% |
| Alivus Life Sciences Ltd | Equity | ₹0.08 Cr | 0.21% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.08 Cr | 0.20% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.07 Cr | 0.18% |
| Sequent Scientific Ltd | Equity | ₹0.07 Cr | 0.18% |
| Senores Pharmaceuticals Ltd | Equity | ₹0.07 Cr | 0.17% |
| FDC Ltd | Equity | ₹0.06 Cr | 0.15% |
| Thyrocare Technologies Ltd | Equity | ₹0.06 Cr | 0.15% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.06 Cr | 0.15% |
| Supriya Lifescience Ltd | Equity | ₹0.06 Cr | 0.14% |
| Blue Jet Healthcare Ltd | Equity | ₹0.05 Cr | 0.14% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.05 Cr | 0.12% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.05 Cr | 0.12% |
| Net Receivables / (Payables) | Cash | ₹0.05 Cr | 0.12% |
| Aarti Drugs Ltd | Equity | ₹0.04 Cr | 0.11% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.04 Cr | 0.11% |
| Morepen Laboratories Ltd | Equity | ₹0.04 Cr | 0.11% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.04 Cr | 0.10% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.04 Cr | 0.10% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.04 Cr | 0.09% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹0.04 Cr | 0.09% |
| Orchid Pharma Ltd | Equity | ₹0.03 Cr | 0.09% |
| Innova Captab Ltd | Equity | ₹0.03 Cr | 0.08% |
| Bliss GVS Pharma Ltd | Equity | ₹0.03 Cr | 0.08% |
| Suven Life Sciences Ltd | Equity | ₹0.03 Cr | 0.08% |
| RPG Life Sciences Ltd | Equity | ₹0.03 Cr | 0.07% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.07% |
| Vimta Labs Ltd | Equity | ₹0.03 Cr | 0.07% |
| Gufic Biosciences Ltd | Equity | ₹0.03 Cr | 0.07% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.07% |
| Unichem Laboratories Ltd | Equity | ₹0.03 Cr | 0.07% |
| Indoco Remedies Ltd | Equity | ₹0.03 Cr | 0.06% |
| Hikal Ltd | Equity | ₹0.02 Cr | 0.06% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.06% |
| 3B BlackBio Dx Ltd | Equity | ₹0.02 Cr | 0.05% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹0.02 Cr | 0.05% |
| Syncom Formulation (India) Ltd | Equity | ₹0.02 Cr | 0.05% |
| Windlas Biotech Ltd | Equity | ₹0.02 Cr | 0.05% |
| Sigachi Industries Ltd | Equity | ₹0.02 Cr | 0.05% |
| Panacea Biotec Ltd | Equity | ₹0.02 Cr | 0.05% |
| Hester Biosciences Ltd | Equity | ₹0.02 Cr | 0.04% |
| Shalby Ltd | Equity | ₹0.02 Cr | 0.04% |
| Fischer Medical Ventures Ltd | Equity | ₹0.02 Cr | 0.04% |
| Bajaj Healthcare Ltd | Equity | ₹0.02 Cr | 0.04% |
| Laxmi Dental Ltd | Equity | ₹0.02 Cr | 0.04% |
| Suraksha Diagnostic Ltd | Equity | ₹0.02 Cr | 0.04% |
| Novartis India Ltd | Equity | ₹0.02 Cr | 0.04% |
| Kwality Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.04% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.03% |
| Wanbury Ltd | Equity | ₹0.01 Cr | 0.03% |
| Kopran Ltd | Equity | ₹0.01 Cr | 0.03% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Jagsonpal Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.03% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.03% |
| Fermenta Biotech Ltd | Equity | ₹0.01 Cr | 0.03% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0.01 Cr | 0.02% |
| Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0.01 Cr | 0.02% |
| Nectar Lifesciences Ltd | Equity | ₹0.01 Cr | 0.02% |
| Anuh Pharma Ltd Shs Dematerialised | Equity | ₹0.01 Cr | 0.02% |
| Shree Ganesh Remedies Ltd Ordinary Shares | Equity | ₹0 Cr | 0.01% |
Large Cap Stocks
45.41%
Mid Cap Stocks
27.68%
Small Cap Stocks
26.80%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹39.16 Cr | 99.13% |
| Basic Materials | ₹0.3 Cr | 0.76% |
Standard Deviation
This fund
16.06%
Cat. avg.
15.84%
Lower the better
Sharpe Ratio
This fund
1.04
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
ISIN INF247L01BB1 | Expense Ratio 0.23% | Exit Load - | Fund Size ₹40 Cr | Age 3 years 5 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹1,44,875 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments